A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
Status:
Completed
Trial end date:
2016-01-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the elimination of guselkumab glycoform variants
following a single intravenous (IV) administration of guselkumab at a 10 milligram per
kilogram (mg/kg) dose in healthy participants.